Adalimumab biosimilar - Amgen

Drug Profile

Adalimumab biosimilar - Amgen

Alternative Names: ABP-501; Adalimumab-atto; AMGEVITA; AMJEVITA

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Ankylosing spondylitis; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis; Uveitis

Most Recent Events

  • 28 Sep 2017 Amgen enters into global settlement agreement with Abbvie related to patent litigation regarding Adalimumab biosimilar
  • 28 Sep 2017 Amgen plans to launch Adalimumab biosimilar in Europe on 16/10/2018
  • 28 Sep 2017 Amgen plans to launch Adalimumab biosimilar in USA on 31/01/2023
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top